Company intelligence / Profile preview

NeuroVigil

Mountain View, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

NeuroVigil's iBrain platform is clinically deployed for remote, non-invasive brain monitoring, primarily in clinical trials and research settings. The technology enables early detection of neurological disease and assessment of disease progression and drug effects by collecting high-fidelity EEG data outside the clinic. Notably, the platform has been validated in collaborations including landmark work with Stephen Hawking and partnerships with pharmaceutical companies such as Roche, and launched commercially within the US in 2024[1][2][3][6].

Therapeutic areas: NeurologyPsychiatry
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Partnerships

Roche

Beyond the preview

Go deeper on NeuroVigil.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroVigil.

Explore the full profile